4-[2-Chloro-6-fluoro-7-(2-methylsulfonylphenyl)quinazolin-4-yl]morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-[2-Chloro-6-fluoro-7-(2-methylsulfonylphenyl)quinazolin-4-yl]morpholine
• 英文别名: 4-[2-chloro-6-fluoro-7-(2-methylsulfonylphenyl)quinazolin-4-yl]morpholine
• 化学式: C₁₉H₁₇ClFN₃O₃S
• 分子量: 421.9
• InChiKey: AAJPHSHYKGMSSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] SUBSTITUTED 5 - (QUINAZOLIN - 2 - YL) PYRIMIDIN- 2 -AMINE DERIVATIVES USEFUL AS PI3K/MTOR INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS 5-(QUINAZOLIN-2-YL)PYRIMIDIN-2-AMINES SUBSTITUÉS UTILES COMME INHIBITEURS DE PI3K/MTOR POUR LE TRAITEMENT DU CANCER
  申请人：ENDO PHARMACEUTICALS INC

  公开号：WO2014022728A1

  公开（公告）日：2014-02-06

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds of formula (I) and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.